Drug Repurposing Market Size, Share & Trends Analysis Report By Disease Area (Oncology, Neurology Disorders, Infectious Diseases, Cardiovascular Conditions, Metabolic Disorders), By Drug Type, By End Use, By Region, And Segment Forecasts, 2025

The global drug repurposing market size was estimated at USD 32.96 billion in 2024 and is projected to reach USD 47.40 billion by 2033, growing at a CAGR of 4.12% from 2025 to 2033. The market has gained significant traction, driven by the potential to offer both cost-effective and time-efficient solutions for pharmaceutical companies.

A critical driver of this growth is the opportunity to leverage existing drugs with well-established safety profiles, significantly reducing the need for lengthy preclinical trials and early-phase clinical development. For instance, in September 2023, the FDA approved empagliflozin (brand name Jardiance), a medication originally developed for type 2 diabetes, for the treatment of chronic kidney disease (CKD) in adults at risk of progression, regardless of diabetes status.

Empagliflozin, developed by Boehringer Ingelheim and Eli Lilly, has shown promising results in clinical trials for reducing the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in CKD patients. While initially approved for type 2 diabetes, this approval extends its potential beyond diabetes management, demonstrating the growing trend of repurposing existing drugs for conditions with limited treatment options. This move highlights the increasing support for drug repurposing efforts and the significant benefits of leveraging established medications for new therapeutic indications.

Furthermore, the rising prevalence of chronic and rare diseases has significantly contributed to the push for repurposed drugs. For example, in December 2022, the FDA approved cariprazine (brand name Vraylar) as an adjunctive treatment for major depressive disorder (MDD) in adults who have had an inadequate response to antidepressant therapy. Cariprazine was originally developed by Gedeon Richter and was first approved by the FDA in 2015 for the treatment of schizophrenia and bipolar I disorder. AbbVie acquired the rights to cariprazine through its acquisition of Allergan in 2020. This approval marks the fourth indication for Vraylar, underscoring the growing trend of repurposing existing medications to address conditions with limited treatment options.

In March 2023, the FDA approved leniolisib (brand name Joenja), a medication originally developed for activated phosphoinositide 3-kinase delta syndrome (APDS), for the treatment of activated PI3K delta syndrome, a rare immune disorder. Leniolisib is a selective inhibitor of the PI3Kδ enzyme, which plays a crucial role in immune cell function. The approval of leniolisib highlights the growing trend of repurposing existing drugs to address rare and orphan diseases, where the development of new drugs can be cost-prohibitive and time-consuming. This strategic move underscores the increasing support for drug repurposing efforts to encourage the development of treatments for conditions with limited therapeutic options.

In drug repurposing, Pfizer has been actively engaged in advancing treatments for prostate cancer. In July 2021, Pfizer entered into a global collaboration with Arvinas to co-develop and co-commercialize ARV-471, an investigational oral PROTAC(R) (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. This partnership aims to leverage existing treatments to address complex and underserved cancers, aligning with Pfizer's broader strategy to expand its oncology portfolio. Additionally, in April 2024, Arvinas entered into a separate licensing and asset-sale agreement with Novartis, valued at over USD 1 billion, for the development and commercialization of ARV-766, a second-generation androgen receptor degrader for prostate cancer. This move underscores the growing interest and investment in repurposing existing drugs to enhance treatment options for prostate cancer patients.

In January 2025, Bayer submitted an sNDA to the U.S. Food and Drug Administration (FDA) seeking approval for Kerendia to treat adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of >=40%, including both mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF). The FDA accepted the application and granted Priority Review designation. The FDA approved this new indication on July 14, 2025, following the agency's Priority Review of its supplemental New Drug Application (sNDA

Global Drug Repurposing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global drug repurposing market report based on Disease Area, drug type, end use, and region :

Disease Area Outlook (Revenue, USD Million, 2021 - 2033)
Oncology
Neurology Disorders
Infectious Diseases
Cardiovascular Conditions
Metabolic Disorders
Others Therapeutic Areas
Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
Conventional Small Molecules
Biologics and Peptide-based Drugs
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Biopharmaceutical & Pharmaceutical Companies
Clinical Research Organizations (CROs)
Universities & Research Institutions
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Product Code: GVR-4-68040-760-1

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Disease Area
- 1.2.2. Drug Type
- 1.2.3. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Drug Repurposing Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis

Chapter 4. Drug Repurposing Market: Disease Area Business Analysis

4.1. Disease Area Market Share, 2024 & 2033
4.2. Disease Area Segment Dashboard
4.3. Global Drug Repurposing Market Size & Forecasts and Trend Analysis, by Disease Area, 2021 to 2033 (USD Million)
4.4. Oncology
- 4.4.1. Oncology Market, 2021 - 2033 (USD Million)
4.5. Neurology Disorders
- 4.5.1. Neurology Disorders Market, 2021 - 2033 (USD Million)
4.6. Infectious Diseases
- 4.6.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
4.7. Cardiovascular Conditions
- 4.7.1. Cardiovascular Conditions Market, 2021 - 2033 (USD Million)
4.8. Metabolic Disorders
- 4.8.1. Metabolic Disorders Market, 2021 - 2033 (USD Million)
4.9. Others Therapeutic Areas
- 4.9.1. Others Therapeutic Areas Market, 2021 - 2033 (USD Million)

Chapter 5. Drug Repurposing Market: Drug Type Business Analysis

5.1. Drug Type Market Share, 2024 & 2033
5.2. Drug Type Segment Dashboard
5.3. Global Drug Repurposing Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
5.4. Conventional Small Molecules
- 5.4.1. Conventional Small Molecules Market, 2021 - 2033 (USD Million)
5.5. Biologics and Peptide-based Drugs
- 5.5.1. Biologics and Peptide-based Drugs Market, 2021 - 2033 (USD Million)

Chapter 6. Drug Repurposing Market: End Use Business Analysis

6.1. End Use Market Share, 2024 & 2033
6.2. End Use Segment Dashboard
6.3. Global Drug Repurposing Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
6.4. Biopharmaceutical & Pharmaceutical Companies
- 6.4.1. Biopharmaceutical & Pharmaceutical Companies Market, 2021 - 2033 (USD Million)
6.5. Clinical Research Organizations (CROs)
- 6.5.1. Clinical Research Organizations (CROs) Market, 2021 - 2033 (USD Million)
6.6. Universities & Research Institutions
- 6.6.1. Universities & Research Institutions Market, 2021 - 2033 (USD Million)

Chapter 7. Drug Repurposing Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2033
7.2. Regional Market Dashboard
7.3. Global Drug Repurposing Market Size & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
- 7.4.1. North America Drug Repurposing Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Regulatory Framework
  - 7.4.2.3. Reimbursement Framework
  - 7.4.2.4. U.S. Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Regulatory Framework
  - 7.4.3.3. Reimbursement Framework
  - 7.4.3.4. U.S. Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Regulatory Framework
  - 7.4.4.3. Reimbursement Framework
  - 7.4.4.4. Mexico Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Europe
- 7.5.1. Europe Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Regulatory Framework
  - 7.5.2.3. Reimbursement Framework
  - 7.5.2.4. UK Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Regulatory Framework
  - 7.5.3.3. Reimbursement Framework
  - 7.5.3.4. Germany Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Regulatory Framework
  - 7.5.4.3. Reimbursement Framework
  - 7.5.4.4. France Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Regulatory Framework
  - 7.5.5.3. Reimbursement Framework
  - 7.5.5.4. Italy Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Regulatory Framework
  - 7.5.6.3. Reimbursement Framework
  - 7.5.6.4. Spain Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Regulatory Framework
  - 7.5.7.3. Reimbursement Framework
  - 7.5.7.4. Denmark Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Regulatory Framework
  - 7.5.8.3. Reimbursement Framework
  - 7.5.8.4. Sweden Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
  - 7.5.9.1. Key Country Dynamics
  - 7.5.9.2. Regulatory Framework
  - 7.5.9.3. Reimbursement Framework
  - 7.5.9.4. Norway Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Asia Pacific
- 7.6.1. Asia Pacific Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Japan
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Regulatory Framework
  - 7.6.2.3. Reimbursement Framework
  - 7.6.2.4. Japan Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Target Disease Prevalence
  - 7.6.3.3. Regulatory Framework
  - 7.6.3.4. Reimbursement Framework
  - 7.6.3.5. China Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Regulatory Framework
  - 7.6.4.3. Reimbursement Framework
  - 7.6.4.4. India Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Regulatory Framework
  - 7.6.5.3. Reimbursement Framework
  - 7.6.5.4. Australia Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Regulatory Framework
  - 7.6.6.3. Reimbursement Framework
  - 7.6.6.4. South Korea Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
  - 7.6.7.1. Key Country Dynamics
  - 7.6.7.2. Regulatory Framework
  - 7.6.7.3. Reimbursement Framework
  - 7.6.7.4. Thailand Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Latin America
- 7.7.1. Latin America Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Regulatory Framework
  - 7.7.2.3. Reimbursement Framework
  - 7.7.2.4. Japan Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Regulatory Framework
  - 7.7.3.3. Reimbursement Framework
  - 7.7.3.4. China Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Regulatory Framework
  - 7.8.2.3. Reimbursement Framework
  - 7.8.2.4. South Africa Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Regulatory Framework
  - 7.8.3.3. Reimbursement Framework
  - 7.8.3.4. Saudi Arabia Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Regulatory Framework
  - 7.8.4.3. Reimbursement Framework
  - 7.8.4.4. UAE Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
  - 7.8.5.1. Key Country Dynamics
  - 7.8.5.2. Regulatory Framework
  - 7.8.5.3. Reimbursement Framework
  - 7.8.5.4. Kuwait Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
- 8.5.1. Eli Lilly and Company
  - 8.5.1.1. Overview
  - 8.5.1.2. Financial Performance
  - 8.5.1.3. Product Benchmarking
  - 8.5.1.4. Strategic Initiatives
- 8.5.2. Pfizer Inc.
  - 8.5.2.1. Overview
  - 8.5.2.2. Financial Performance
  - 8.5.2.3. Product Benchmarking
  - 8.5.2.4. Strategic Initiatives
- 8.5.3. Roche Holding AG
  - 8.5.3.1. Overview
  - 8.5.3.2. Financial Performance
  - 8.5.3.3. Product Benchmarking
  - 8.5.3.4. Strategic Initiatives
- 8.5.4. Novartis AG
  - 8.5.4.1. Overview
  - 8.5.4.2. Financial Performance
  - 8.5.4.3. Product Benchmarking
  - 8.5.4.4. Strategic Initiatives
- 8.5.5. Bayer AG
  - 8.5.5.1. Overview
  - 8.5.5.2. Financial Performance
  - 8.5.5.3. Product Benchmarking
  - 8.5.5.4. Strategic Initiatives
- 8.5.6. GSK plc
  - 8.5.6.1. Overview
  - 8.5.6.2. Financial Performance
  - 8.5.6.3. Product Benchmarking
  - 8.5.6.4. Strategic Initiatives
- 8.5.7. Amgen Inc.
  - 8.5.7.1. Overview
  - 8.5.7.2. Financial Performance
  - 8.5.7.3. Product Benchmarking
  - 8.5.7.4. Strategic Initiatives
- 8.5.8. Biogen Inc.
  - 8.5.8.1. Overview
  - 8.5.8.2. Financial Performance
  - 8.5.8.3. Product Benchmarking
  - 8.5.8.4. Strategic Initiatives
- 8.5.9. Teva Pharmaceutical
  - 8.5.9.1. Overview
  - 8.5.9.2. Financial Performance
  - 8.5.9.3. Product Benchmarking
  - 8.5.9.4. Strategic Initiatives
- 8.5.10. Vertex Pharmaceuticals
  - 8.5.10.1. Overview
  - 8.5.10.2. Financial Performance
  - 8.5.10.3. Product Benchmarking
  - 8.5.10.4. Strategic Initiatives

Product Code: GVR-4-68040-760-1

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global drug repurposing market, by region, 2021 - 2033 (USD Million)
Table 4 Global drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 5 Global drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 6 Global drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 7 North America drug repurposing market, by country, 2021 - 2033 (USD Million)
Table 8 North America drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 9 North America drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 10 North America drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 11 U.S drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 12 U.S drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 13 U.S drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 14 Canada drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 15 Canada drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 16 Canada drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 17 Mexico drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 18 Mexico drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 19 Mexico drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 20 Europe drug repurposing market, by country, 2021 - 2033 (USD Million)
Table 21 Europe drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 22 Europe drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 23 Europe drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 24 UK drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 25 UK drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 26 UK drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 27 Germany drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 28 Germany drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 29 Germany drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 30 France drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 31 France drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 32 France drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 33 Italy drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 34 Italy drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 35 Italy drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 36 Spain drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 37 Spain drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 38 Spain drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 39 Norway drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 40 Norway drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 41 Norway drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 42 Denmark drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 43 Denmark drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 44 Denmark drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 45 Sweden drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 46 Sweden drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 47 Sweden drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 48 Asia Pacific drug repurposing market, by country, 2021 - 2033 (USD Million)
Table 49 Asia Pacific drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 50 Asia Pacific drug repurposing market, by drug type , 2021-2033, (USD
Table 51 Asia Pacific drug repurposing market, by end use , 2021-2033, (USD Million)
Table 52 Japan drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 52 Japan drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 54 Japan drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 55 China drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 56 China drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 57 China drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 58 India drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 69 India drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 70 India drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 71 Australia drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 72 Australia drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 73 Australia drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 74 South Korea drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 75 South Korea drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 76 South Korea drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 77 Thailand drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 78 Thailand drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 89 Thailand drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 80 Latin America drug repurposing market, by country, 2021 - 2033 (USD Million)
Table 81 Latin America drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 82 Latin America drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 83 Latin America drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 84 Brazil drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 85 Brazil drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 86 Brazil drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 87 Argentina drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 88 Argentina drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 89 Argentina drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 90 Middle East & Africa Drug repurposing market, by country, 2021 - 2033 (USD Million)
Table 91 Middle East & Africa drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 92 Middle East & Africa drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 93 Middle East & Africa drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 94 South Africa drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 95 South Africa drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 96 South Africa drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 97 Saudi Arabia drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 98 Saudi Arabia drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 99 Saudi Arabia drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 100 UAE drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 101 UAE drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 102 UAE drug repurposing market, by end use , 2021 - 2033 (USD Million)
Table 103 Kuwait drug repurposing market, by disease area, 2021 - 2033 (USD Million)
Table 104 Kuwait drug repurposing market, by drug type , 2021 - 2033 (USD Million)
Table 105 Kuwait drug repurposing market, by end use , 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Drug repurposing market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and disease area outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Drug repurposing market dynamics
Fig. 12 Drug repurposing market: Porter's five forces analysis
Fig. 13 Drug repurposing market: PESTLE analysis
Fig. 14 Oncology market, 2021 - 2033 (USD Million)
Fig. 15 Neurology Disorders market, 2021 - 2033 (USD Million)
Fig. 16 Infectious Diseases market, 2021 - 2033 (USD Million)
Fig. 17 Cardiovascular Conditions market, 2021 - 2033 (USD Million)
Fig. 18 Metabolic Disorders market, 2021 - 2033 (USD Million)
Fig. 19 Others Therapeutic Areas market, 2021 - 2033 (USD Million)
Fig. 20 Drug Type market, 2021 - 2033 (USD Million)
Fig. 21 Conventional Small Molecules market, 2021 - 2033 (USD Million)
Fig. 22 Biologics and Peptide-based Drugs market, 2021 - 2033 (USD Million)
Fig. 23 End Use market, 2021 - 2033 (USD Million)
Fig. 24 Biopharmaceutical & Pharmaceutical Companies market, 2021 - 2033 (USD Million)
Fig. 25 Clinical Research Organizations (CROs) market, 2021 - 2033 (USD Million)
Fig. 26 Universities & Research Institutions market, 2021 - 2033 (USD Million)
Fig. 27 Drug repurposing market revenue, by region
Fig. 28 Regional marketplace: Key takeaways
Fig. 29 North America drug repurposing market, 2021 - 2033 (USD Million)
Fig. 30 U.S. country dynamics
Fig. 31 U.S. drug repurposing market, 2021 - 2033 (USD Million)
Fig. 32 Canada country dynamics
Fig. 33 Canada drug repurposing market, 2021 - 2033 (USD Million)
Fig. 34 Mexico country dynamics
Fig. 35 Mexico drug repurposing market, 2021 - 2033 (USD Million)
Fig. 36 Europe drug repurposing market, 2021 - 2033 (USD Million)
Fig. 37 UK country dynamics
Fig. 38 UK drug repurposing market, 2021 - 2033 (USD Million)
Fig. 39 Germany country dynamics
Fig. 40 Germany drug repurposing market, 2021 - 2033 (USD Million)
Fig. 41 France country dynamics
Fig. 42 France drug repurposing market, 2021 - 2033 (USD Million)
Fig. 43 Italy country dynamics
Fig. 44 Italy drug repurposing market, 2021 - 2033 (USD Million)
Fig. 45 Spain country dynamics
Fig. 46 Spain drug repurposing market, 2021 - 2033 (USD Million)
Fig. 47 Norway country dynamics
Fig. 48 Norway drug repurposing market, 2021 - 2033 (USD Million)
Fig. 49 Sweden country dynamics
Fig. 50 Sweden drug repurposing market, 2021 - 2033 (USD Million)
Fig. 51 Denmark country dynamics
Fig. 52 Denmark drug repurposing market, 2021 - 2033 (USD Million)
Fig. 53 Asia Pacific drug repurposing market, 2021 - 2033 (USD Million)
Fig. 54 Japan country dynamics
Fig. 55 Japan drug repurposing market, 2021 - 2033 (USD Million)
Fig. 56 China country dynamics
Fig. 57 China drug repurposing market, 2021 - 2033 (USD Million)
Fig. 58 India country dynamics
Fig. 59 India drug repurposing market, 2021 - 2033 (USD Million)
Fig. 60 Australia country dynamics
Fig. 61 Australia drug repurposing market, 2021 - 2033 (USD Million)
Fig. 62 South Korea country dynamics
Fig. 63 South Korea drug repurposing market, 2021 - 2033 (USD Million)
Fig. 64 Thailand country dynamics
Fig. 65 Thailand drug repurposing market, 2021 - 2033 (USD Million)
Fig. 66 Latin America drug repurposing market, 2021 - 2033 (USD Million)
Fig. 67 Brazil country dynamics
Fig. 68 Brazil drug repurposing market, 2021 - 2033 (USD Million)
Fig. 69 Argentina country dynamics
Fig. 70 Argentina drug repurposing market, 2021 - 2033 (USD Million)
Fig. 71 Middle East and Africa drug repurposing market, 2021 - 2033 (USD Million)
Fig. 72 South Africa country dynamics
Fig. 73 South Africa drug repurposing market, 2021 - 2033 (USD Million)
Fig. 74 Saudi Arabia country dynamics
Fig. 75 Saudi Arabia drug repurposing market, 2021 - 2033 (USD Million)
Fig. 76 UAE country dynamics
Fig. 77 UAE drug repurposing market, 2021 - 2033 (USD Million)
Fig. 78 Kuwait country dynamics
Fig. 79 Kuwait drug repurposing market, 2021 - 2033 (USD Million)
Fig. 80 Company categorization
Fig. 81 Company market position analysis
Fig. 82 Strategic framework

Drug Repurposing Market Size, Share & Trends Analysis Report By Disease Area (Oncology, Neurology Disorders, Infectious Diseases, Cardiovascular Conditions, Metabolic Disorders), By Drug Type, By End Use, By Region, And Segment Forecasts, 2025 - 2033

Description

Table of Contents

List of Tables

Drug Repurposing Market Summary

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Drug Repurposing Market Variables, Trends, & Scope

Chapter 4. Drug Repurposing Market: Disease Area Business Analysis

Chapter 5. Drug Repurposing Market: Drug Type Business Analysis

Chapter 6. Drug Repurposing Market: End Use Business Analysis

Chapter 7. Drug Repurposing Market: Regional Estimates & Trend Analysis

Chapter 8. Competitive Landscape

List of Tables

List of Figures